Please use this identifier to cite or link to this item: https://doi.org/10.1080/14712598.2018.1448382
DC FieldValue
dc.titleSources of variability in quantifying circulating thymosin beta-4: literature review and recommendations
dc.contributor.authorTan, Warren KY
dc.contributor.authorPurnamawati, Kristy
dc.contributor.authorPakkiri, Leroy S
dc.contributor.authorTan, Sock Hwee
dc.contributor.authorYang, Xiaoxun
dc.contributor.authorChan, Mark Y
dc.contributor.authorDrum, Chester L
dc.date.accessioned2021-11-12T01:35:30Z
dc.date.available2021-11-12T01:35:30Z
dc.date.issued2018-01-01
dc.identifier.citationTan, Warren KY, Purnamawati, Kristy, Pakkiri, Leroy S, Tan, Sock Hwee, Yang, Xiaoxun, Chan, Mark Y, Drum, Chester L (2018-01-01). Sources of variability in quantifying circulating thymosin beta-4: literature review and recommendations. EXPERT OPINION ON BIOLOGICAL THERAPY 18 (sup1) : 141-147. ScholarBank@NUS Repository. https://doi.org/10.1080/14712598.2018.1448382
dc.identifier.issn14712598
dc.identifier.issn17447682
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/206024
dc.description.abstractIntroduction: Thymosin beta-4 (TB4) is an endogenous peptide with protective and regenerative effects in models of cellular and organ injury. TB4 is increasingly measured as a potential plasma or serum biomarker in human cardiovascular, liver, infectious, and autoimmune disease. Areas covered: The focus of this review is the quantification of TB4 in clinical cohort studies and whether reported TB4 concentrations differ with respect to method of sample preparation. We survey current literature for studies measuring TB4 in human serum or plasma and compare reported concentrations in healthy controls. Expert opinion: We find substantial intra- and inter- study variability in healthy controls, and a lack of protocol standardization. We further highlight three factors that may confound TB4 clinical measurements and should be considered in future study design: 1) residual platelets remaining in suspension after centrifugation, 2) TB4 release following ex vivo platelet activation, and 3) specificity of assays towards posttranslational modifications. Accordingly, we put forth our recommendations to minimize residual and activated platelets during sample collection, and to cross-validate TB4 measurements using both antibody-based and mass spectrometry-based methods.
dc.language.isoen
dc.publisherTAYLOR & FRANCIS LTD
dc.sourceElements
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectBiotechnology & Applied Microbiology
dc.subjectMedicine, Research & Experimental
dc.subjectResearch & Experimental Medicine
dc.subjectThymosin beta-4
dc.subjectplasma
dc.subjectserum
dc.subjectbiomarker
dc.subjectplatelets
dc.subjectHUMAN BLOOD-PLATELETS
dc.subjectRHEUMATOID-ARTHRITIS
dc.subjectPLASMA
dc.subjectSERUM
dc.subjectPEPTIDES
dc.subjectBETA(4)
dc.subjectCENTRIFUGATION
dc.subjectACTIVATION
dc.subjectTHERAPY
dc.typeReview
dc.date.updated2021-11-10T05:01:10Z
dc.contributor.departmentDEPT OF MEDICINE
dc.description.doi10.1080/14712598.2018.1448382
dc.description.sourcetitleEXPERT OPINION ON BIOLOGICAL THERAPY
dc.description.volume18
dc.description.issuesup1
dc.description.page141-147
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Sources of variability in quantifying circulating thymosin beta 4 literature review and recommendations.pdfPublished version1.72 MBAdobe PDF

CLOSED

None

SCOPUSTM   
Citations

6
checked on Jun 30, 2022

Page view(s)

54
checked on Jun 23, 2022

Download(s)

1
checked on Jun 23, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.